Orbimed Advisors LLC acquired a new stake in shares of Upstream Bio, Inc. (NASDAQ:UPB - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 5,693,589 shares of the company's stock, valued at approximately $93,603,000. Upstream Bio accounts for about 2.1% of Orbimed Advisors LLC's investment portfolio, making the stock its 14th biggest holding. Orbimed Advisors LLC owned approximately 10.62% of Upstream Bio at the end of the most recent quarter.
Other institutional investors have also recently made changes to their positions in the company. BNP Paribas Financial Markets purchased a new stake in shares of Upstream Bio during the fourth quarter valued at approximately $25,000. US Bancorp DE purchased a new stake in Upstream Bio in the fourth quarter worth $27,000. Legal & General Group Plc bought a new stake in Upstream Bio in the fourth quarter valued at $28,000. Summit Investment Advisors Inc. purchased a new position in Upstream Bio during the 4th quarter valued at $30,000. Finally, Tower Research Capital LLC TRC bought a new position in Upstream Bio in the 4th quarter worth $47,000.
Upstream Bio Stock Down 1.6%
NASDAQ UPB traded down $0.14 during trading on Friday, hitting $8.64. The company had a trading volume of 318,862 shares, compared to its average volume of 326,656. Upstream Bio, Inc. has a one year low of $5.14 and a one year high of $29.46. The company's fifty day moving average is $8.06 and its 200-day moving average is $12.94.
Upstream Bio (NASDAQ:UPB - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.02). The business had revenue of $0.57 million for the quarter, compared to analyst estimates of $0.71 million. Equities analysts expect that Upstream Bio, Inc. will post -4.3 earnings per share for the current year.
Upstream Bio Company Profile
(
Free Report)
Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
Recommended Stories
Before you consider Upstream Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Upstream Bio wasn't on the list.
While Upstream Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
